As U.S. lawmakers continue to debate health care issues concerning transgender youth, a recent study published in a medical journal has shed light on the actual number of young people receiving gender-affirming medications. The study revealed that fewer than 1 in 1,000 U.S. adolescents with commercial insurance received gender-affirming medications, such as puberty blockers or hormones, over a five-year period.
These findings come at a crucial time as at least 26 states have implemented laws restricting or banning gender-affirming medical care for transgender minors, leading to legal challenges in many of these states. The U.S. Supreme Court is currently considering a case from Tennessee that could have significant implications for transgender health care.
